Modelling links earlier global COVID-19 vaccination to over 8 million lives

Beginning the global COVID-19 vaccine roll-out 100 days after the SARS-CoV-2 genome was sequenced could have saved more than 8 million lives by the end of 2021, according to modelling evidence reviewed in a United Nations University policy brief. Most of the estimated lives saved would have been in lower-middle-income countries, where delayed access to vaccines left the pandemic’s burden concentrated among poorer populations. The estimate assumes that other public-health measures followed their historical course and that high vaccination coverage was reached before the Delta variant spread. The brief also concludes that faster delivery alone would not have been sufficient: parallel investment in vaccine manufacturing and health-system capacity could have saved a further 3 million lives.

The findings were assembled by researchers from the United Nations University Institute for Water, Environment and Health, the University of Oxford, Imperial College London, the London School of Hygiene and Tropical Medicine, King’s College London, Nagasaki University, the Japan Institute for Health Security, the Public Health Foundation of India and the Middle East Liver Disease Center. Published in October 2026 as “Best Practices in Global Vaccination Roll-Out to Reduce Health Inequity,” the policy brief reviews modelling studies and peer-reviewed evidence on the unequal timing and scale of COVID-19 vaccination. It accompanies a September 2026 publication in the journal Expert Review of Vaccines. The analysis concerns pandemic preparedness rather than a new clinical trial, and its central mortality figures are counterfactual model estimates rather than deaths directly observed after a policy intervention.

COVID-19 vaccines were introduced across countries more quickly and, by some measures, more equitably than earlier vaccines, yet access remained sharply unequal. By the end of 2021, high- and upper-middle-income countries had administered at least one dose per person on average. In contrast, lower-middle-income countries had administered one dose for every three people, while low-income countries had administered one for every 25 people. The disparity is historically unusual: earlier vaccines against Haemophilus influenzae type b and human papillomavirus often reached low-income countries 10 to 30 years after reaching high-income countries. Thus, the speed of COVID-19 vaccine development represented a scientific achievement, but the distribution system did not ensure that protection arrived with comparable speed or scale.

Several studies reviewed in the publication estimate the potential effect of narrowing the roll-out gap. If lower-middle- and low-income countries had matched the vaccination rates of high-income countries, as many as half of their COVID-19 deaths might have been averted by 1 October 2021. A separate estimate suggests that more equitable sharing of existing vaccine supply could have prevented 1.3 million deaths worldwide by the end of 2021. These are modelled counterfactual scenarios, not evaluations of a vaccination programme in which the proposed changes were fully implemented. They indicate the scale of the inequity documented by the research. The publication also reports that vaccination averted far fewer deaths per capita in low-income countries, particularly in the Eastern Mediterranean and African regions, than in high-income countries.

Delayed protection in lower-resource settings also had consequences beyond mortality. Prolonged opportunities for transmission increased the risk that new variants could emerge, while slower control of the epidemic weakened economic recovery and reduced health and economic security across national borders. The modelling reviewed by the brief estimated the lives saved by an earlier roll-out at more than 8 million, with those life-years valued at US$14 trillion. Parallel investment in manufacturing capacity and health systems was associated with an additional modelled 3 million lives saved and a corresponding monetary value of US$5 trillion. These valuation figures are model outputs that translate mortality effects into economic terms; they are not direct measurements of realised savings.

The authors propose an “equity-by-design” framework in which vaccine development is linked systematically to financing, procurement, manufacturing, allocation, delivery, uptake, safety monitoring and accountability. The approach is intended to translate broad commitments to pandemic solidarity into mechanisms that can operate before the next emergency. It draws on the World Health Organization Pandemic Agreement, adopted in May 2025, and amended International Health Regulations, in force for most States Parties since September 2025. The brief argues that allocation principles should be established in advance so that limited supplies can be distributed according to epidemiological evidence, including disease burden, risk of severe outcomes and transmission speed, rather than negotiated after a crisis has begun.

Six practical recommendations structure the proposed framework. Governments and international organisations should prepare pooled procurement, research funding, surveillance, scalable manufacturing, supply chains and regional stockpiles before an emergency. Vaccine allocation should build on COVAX’s pooled-demand and needs-based approach while adding earlier and predictable finance, enforceable access commitments, predefined dose-sharing triggers and public tracking of roll-out timelines. Advance purchase agreements should require transparent prices, flexible delivery and automatic sharing when agreed triggers are met, while diversified vaccine portfolios could reduce supply risks. The recommendations also call for transparent reporting of cases, hospital admissions, deaths, adverse events and vaccination by age, sex, geography and risk group in standard, machine-readable formats, supported by community engagement and monitoring of misinformation.

International institutions and national authorities are further advised to insulate vaccine policy from political distortion by strengthening regulatory standards and independent advisory committees, and to support rather than penalise countries that report outbreaks and dangerous variants early. The research team argues that punitive responses, including travel restrictions, may have discouraged timely reporting during COVID-19. Timely sharing of high-quality, geographically representative genomic data should instead be encouraged through recognition of contributors and equitable access to benefits, including vaccines and other countermeasures. Sustained investment in pathogen surveillance, sequencing, analysis and workforce training is also needed to detect emerging threats and inform vaccine responses. The proposal is intended to make surveillance and data sharing part of preparedness, rather than treating them as separate from the vaccine system.

Delivery capacity and regional production form the final foundation of the framework. The authors caution that regional manufacturing is not a stand-alone solution: it requires long-term demand, predictable finance, regulatory convergence and a skilled workforce. Health facilities, trained personnel, cold chains and real-time monitoring of vaccine stocks and temperatures must also be strengthened, particularly in low-resource and conflict-affected settings. Within countries, vaccination should be targeted toward vulnerable and high-risk groups using models that account for health and socioeconomic vulnerability, with independent national oversight. The study therefore treats equity as an operational property of the entire vaccine system, linking surveillance and innovation to manufacturing, procurement, allocation and last-mile delivery rather than treating equitable access as a distribution step added after production.

The policy brief does not report a retrospective vaccination programme that prevented all of the modelled deaths; instead, it quantifies losses associated with a historically unequal roll-out and identifies mechanisms intended to prevent repetition. Its central technical conclusion is that pandemic technologies cannot deliver their full public-health value unless financing, supply allocation, manufacturing and health-system delivery are designed in advance around equity. A start 100 days after viral sequencing might have saved more than 8 million lives, but the additional 3 million-life estimate from parallel capacity investments shows why the broader response also matters. The proposed solution is a pre-agreed global operating system for vaccine access, one that can turn scientific speed into timely protection across countries by ensuring that surveillance, finance, production and delivery are addressed together before the next health emergency.

Subject of Research: Modelled effects of global COVID-19 vaccine equity and pandemic preparedness

Article Title: Scientific triumph, equity failure: Faster, fairer COVID-19 vaccine roll-out could have saved millions of lives, UN University publication reveals

Article References: Scientific triumph, equity failure: Faster, fairer COVID-19 vaccine roll-out could have saved millions of lives, UN University publication reveals. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: COVID-19 vaccines, vaccine equity, pandemic preparedness, global health, health inequity, vaccine allocation, regional manufacturing, genomic surveillance, United Nations University, health systems, Scientific, triumph